Marstacimab: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 05:21, 21 September 2024 editWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,185 edits templates← Previous edit		Revision as of 00:11, 22 September 2024 edit undoWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,185 edits infoboxNext edit →
Line 23:		Line 23:
	\| pregnancy_AU_comment =		\| pregnancy_AU_comment =
	\| pregnancy_category =		\| pregnancy_category =
	\| dependency_liability =
	\| addiction_liability =
	\| routes_of_administration =		\| routes_of_administration =
	\| class =		\| class =

Revision as of 00:11, 22 September 2024

Medication

Pharmaceutical compound

Marstacimab
Clinical data
Other names	PF-06741086
ATC code	None
Identifiers
CAS Number	1985638-39-8
DrugBank	DB17725
UNII	0UB3OA67O7
KEGG	D11261

Marstacimab is an experimental monoclonal antibody intended for the treatment of hemophilia A and B. It is being developed by Pfizer.

Society and culture

Legal status

In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hympavzi, intended for prophylaxis of bleeding episodes in people aged twelve years of age and older, weighing at least 35 kilograms (77 lb), who have severe hemophilia A or B. The applicant for this medicinal product is Pfizer Europe Ma EEIG.

Names

Marstacimab is the international nonproprietary name.

References

^ "Hympavzi EPAR". European Medicines Agency (EMA). 19 September 2024. Retrieved 21 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B". Pfizer (Press release). 9 December 2023. Retrieved 21 September 2024.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

External links

Clinical trial number NCT03938792 for "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B" at ClinicalTrials.gov

Antihemorrhagics (B02)

Antihemorrhagics
(coagulation)

Systemic

Vitamin K

Coagulation
factors

intrinsic:
VIII/(Damoctocog alfa pegol, Efanesoctocog alfa, Efmoroctocog alfa, Moroctocog alfa, Susoctocog alfa, Turoctocog alfa, Valoctocogene roxaparvovec, von Willebrand factor)
IX/(Fidanacogene elaparvovec, Nonacog alfa)

extrinsic: VII/Eptacog alfa

combinations: Prothrombin complex concentrate (II, VII, IX, X, protein C and S)

Other
systemic

Local

Antifibrinolytics

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Musculoskeletal

Human	Stamulumab

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Portal:

Medicine

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories: